You are now subscribed
Your newsletter sign-up was successful
Want to add more newsletters?
Delivered daily
Kiplinger Today
Profit and prosper with the best of Kiplinger's advice on investing, taxes, retirement, personal finance and much more delivered daily. Smart money moves start here.
Sent five days a week
Kiplinger A Step Ahead
Get practical help to make better financial decisions in your everyday life, from spending to savings on top deals.
Delivered daily
Kiplinger Closing Bell
Get today's biggest financial and investing headlines delivered to your inbox every day the U.S. stock market is open.
Sent twice a week
Kiplinger Adviser Intel
Financial pros across the country share best practices and fresh tactics to preserve and grow your wealth.
Delivered weekly
Kiplinger Tax Tips
Trim your federal and state tax bills with practical tax-planning and tax-cutting strategies.
Sent twice a week
Kiplinger Retirement Tips
Your twice-a-week guide to planning and enjoying a financially secure and richly rewarding retirement
Sent bimonthly.
Kiplinger Adviser Angle
Insights for advisers, wealth managers and other financial professionals.
Sent twice a week
Kiplinger Investing Weekly
Your twice-a-week roundup of promising stocks, funds, companies and industries you should consider, ones you should avoid, and why.
Sent weekly for six weeks
Kiplinger Invest for Retirement
Your step-by-step six-part series on how to invest for retirement, from devising a successful strategy to exactly which investments to choose.
Biotech giant Genentech's latest earnings report signaled blue skies for the company, with the exception of one ominous storm cloud: Avastin. Despite posting a nearly 80% jump in profits during the second quarter, Genentech's stock has taken a 4% dive since its earnings release Tuesday. The drop stems from disappointing quarterly sales of colon-cancer drug Avastin, which missed analysts' expectations with revenues of $423 million versus Wall Street's $439 million estimate. (That ought to give us an idea of how short Wall Street's hair-trigger is.) Also not helping matters: Genentech announced a potential delay in regulatory approval of Avastin for use in treating breast cancer.
But Avastin's drag on the stock is offset by other growth drivers in the company's drug lineup, Piper Jaffray analyst Thomas Wei told clients on Wednesday. He thinks the Avastin dustup is a buying opportunity. Wei notes that several new noncancer drugs, such as Lucentis and Rituxan, offer growth potential. Wei says Genentech remains "one of" the best high-quality biotech stocks, rates it a "buy" and has a $117 one-year target price for the stock (symbol DNA). The shares traded at $81 Thursday.
Genentech's shares, which cracked $100 in December 2005, fell to $81 in early March and have since seesawed. For the second quarter ending June 30, the South San Francisco company reported earnings of 49 cents a share on sales of $2.2 billion, compared with 27 cents a share and $1.5 billion a year earlier. Based on strong sales of its stable of anticancer drugs, Genentech raised its 2006 forecast for earnings growth to a range of 55% to 60% from a previous estimate of 45% to 55%.
From just $107.88 $24.99 for Kiplinger Personal Finance
Become a smarter, better informed investor. Subscribe from just $107.88 $24.99, plus get up to 4 Special Issues
Sign up for Kiplinger’s Free Newsletters
Profit and prosper with the best of expert advice on investing, taxes, retirement, personal finance and more - straight to your e-mail.
Profit and prosper with the best of expert advice - straight to your e-mail.
Morgan Stanley analyst Steven Harr also maintained an "overweight" rating on Genentech and raised his target price to $92 from $90 on Wednesday. "The light quarter is likely to pause the stock's recent upward trend," he wrote in a note to clients. "However, we continue to have significant conviction in the stock."
Opinions on this volatile stock aren't unanimous. Ron Ellis of Prudential Equity group downgraded Genentech based on "reduced market opportunity" for Avastin, and dropped his price target to $84 from $94.
Like many biotechnology stocks, Genentech isn't cheap on a price-to-earnings basis. At $81, the stock trades at 40 times analysts' 2006 earnings estimate of $2.02 per share, and 31 times the 2007 estimate of $2.59, according to Thomson First Call.
-
Dow Leads in Mixed Session on Amgen Earnings: Stock Market TodayThe rest of Wall Street struggled as Advanced Micro Devices earnings caused a chip-stock sell-off.
-
How to Watch the 2026 Winter Olympics Without OverpayingHere’s how to stream the 2026 Winter Olympics live, including low-cost viewing options, Peacock access and ways to catch your favorite athletes and events from anywhere.
-
Here’s How to Stream the Super Bowl for LessWe'll show you the least expensive ways to stream football's biggest event.
-
If You'd Put $1,000 Into AMD Stock 20 Years Ago, Here's What You'd Have TodayAdvanced Micro Devices stock is soaring thanks to AI, but as a buy-and-hold bet, it's been a market laggard.
-
If You'd Put $1,000 Into UPS Stock 20 Years Ago, Here's What You'd Have TodayUnited Parcel Service stock has been a massive long-term laggard.
-
How the Stock Market Performed in the First Year of Trump's Second TermSix months after President Donald Trump's inauguration, take a look at how the stock market has performed.
-
If You'd Put $1,000 Into Lowe's Stock 20 Years Ago, Here's What You'd Have TodayLowe's stock has delivered disappointing returns recently, but it's been a great holding for truly patient investors.
-
If You'd Put $1,000 Into 3M Stock 20 Years Ago, Here's What You'd Have TodayMMM stock has been a pit of despair for truly long-term shareholders.
-
If You'd Put $1,000 Into Coca-Cola Stock 20 Years Ago, Here's What You'd Have TodayEven with its reliable dividend growth and generous stock buybacks, Coca-Cola has underperformed the broad market in the long term.
-
If You Put $1,000 into Qualcomm Stock 20 Years Ago, Here's What You Would Have TodayQualcomm stock has been a big disappointment for truly long-term investors.
-
If You'd Put $1,000 Into Home Depot Stock 20 Years Ago, Here's What You'd Have TodayHome Depot stock has been a buy-and-hold banger for truly long-term investors.
